[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].Ugeskr Laeger. 2011 Feb 21; 173(8):564-7.UL
Abstract
In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension. No studies with rimonabant fulfilled the inclusion criteria. The weight loss was larger in the groups treated with orlistat or sibutramine compared with placebo therapy. Orlistat reduced systolic and diastolic blood pressure more than placebo, while blood pressure increased during treatment with sibutramine. The studies were too small and of too short duration to allow an evaluation of the effect on cardiovascular mortality and morbidity.
MeSH
Pub Type(s)
Journal Article
Language
dan
PubMed ID
21333255
Citation
Madsbad, Sten. "[Long-term Effects of Weight-reducing Drugs in Hypertensive Patients--a Survey of a Cochrane Review]." Ugeskrift for Laeger, vol. 173, no. 8, 2011, pp. 564-7.
Madsbad S. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskr Laeger. 2011;173(8):564-7.
Madsbad, S. (2011). [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for Laeger, 173(8), 564-7.
Madsbad S. [Long-term Effects of Weight-reducing Drugs in Hypertensive Patients--a Survey of a Cochrane Review]. Ugeskr Laeger. 2011 Feb 21;173(8):564-7. PubMed PMID: 21333255.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
A1 - Madsbad,Sten,
PY - 2011/2/22/entrez
PY - 2011/2/22/pubmed
PY - 2011/3/26/medline
SP - 564
EP - 7
JF - Ugeskrift for laeger
JO - Ugeskr Laeger
VL - 173
IS - 8
N2 - In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension. No studies with rimonabant fulfilled the inclusion criteria. The weight loss was larger in the groups treated with orlistat or sibutramine compared with placebo therapy. Orlistat reduced systolic and diastolic blood pressure more than placebo, while blood pressure increased during treatment with sibutramine. The studies were too small and of too short duration to allow an evaluation of the effect on cardiovascular mortality and morbidity.
SN - 1603-6824
UR - https://www.unboundmedicine.com/medline/citation/21333255/[Long_term_effects_of_weight_reducing_drugs_in_hypertensive_patients__a_survey_of_a_Cochrane_review]_
L2 - https://medlineplus.gov/obesity.html
DB - PRIME
DP - Unbound Medicine
ER -